Efficacy of stereotactic body radiation therapy with γ-knife combined with targeted drug sorafenib in treatment of recurrent and metastatic renal cell carcinoma
KANG Jingbo, NIE Qing, ZHANG Liping, ZHANG Jun, LI Qiliang, and ZHU Qi
Department of Radiation Oncology, Navy General Hospital of PLA，Beijing 100048，China
Abstract：Objective To study the efficacy of stereotactic radiation therapy with gamma-knife (γ-SBRT) combined with targeted drug sorafenib in treatment of recurrent and metastatic renal cell carcinoma. Methods From May 2007 to May 2009, 45 patients with recurrent and metastatic renal cell carcinoma patients were admitted. 26 of them were treated with γ-SBRT alone and 19 cases treated with γ-SBRT with Sorafenib treatment. Results The total effective rate after three-month treatment was 80.0% (36/45). The local control rate at 1, 2 years was 42.3% (11/26), 19.2% (5/26)，median survival 12 months, and the cumulative survival rate at 1, 2 years was 46.2 %, 19.2%, respectively in γ-SBRT group. The local control rate at 1, 2 years was 47.3% (18/19) and 21.1% (4/19)，median survival 18 months, and the cumulative survival rate at 1, 2 years was 57.9% and 26.3%, respectively inγ-SBRT + sorafenib group. Conclusions The combination of stereotactic gamma-body radiation therapy with targeted drug sorafenib for treatment of recurrent and metastatic renal cell carcinoma is an effective treatment. Adverse reactions are mild, and most patients can tolerate the treatment.
康静波，聂青，张丽萍，张军，李启亮，朱奇. 立体定向放射治疗配合靶向药物索拉非尼治疗复发[J]. 武警医学, 2012, 23(6): 465-467.
KANG Jingbo, NIE Qing, ZHANG Liping, ZHANG Jun, LI Qiliang, and ZHU Qi. Efficacy of stereotactic body radiation therapy with γ-knife combined with targeted drug sorafenib in treatment of recurrent and metastatic renal cell carcinoma. Med. J. Chin. Peop. Armed Poli. Forc., 2012, 23(6): 465-467.
